Literature DB >> 12709842

Comparative in vitro surveillance of amoxicillin-clavulanic acid and four oral comparators against 21232 clinical isolates from europe.

D J Hoban1, S K Bouchillon, J L Johnson, G G Zhanel, D L Butler, K A Saunders, L A Miller, J A Poupard.   

Abstract

The present study was conducted to determine the in vitro activity of amoxicillin-clavulanic acid compared to that of four newer antimicrobial agents (ampicillin, azithromycin, cefuroxime and trimethoprim-sulfamethoxazole). All of the agents were tested against 21232 recent clinical isolates encompassing 37 species submitted from 16 European countries between 1997 and 1999. After 20 years of clinical use, amoxicillin-clavulanic acid continues to retain much of its initial activity against targeted gram-positive organisms, selected gram-negative organisms and major respiratory pathogens.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12709842     DOI: 10.1007/s10096-002-0876-0

Source DB:  PubMed          Journal:  Eur J Clin Microbiol Infect Dis        ISSN: 0934-9723            Impact factor:   3.267


  13 in total

1.  The current status of surveillance of resistance to antimicrobial agents: report on a meeting.

Authors:  Pamela A Hunter; David S Reeves
Journal:  J Antimicrob Chemother       Date:  2002-01       Impact factor: 5.790

Review 2.  Clinical implications of antimicrobial resistance: how big is the problem?

Authors:  Georgia Duckworth
Journal:  Int J Infect Dis       Date:  2002-03       Impact factor: 3.623

Review 3.  Surveillance of antimicrobial resistance--what, how and whither?

Authors:  R Bax; R Bywater; G Cornaglia; H Goossens; P Hunter; V Isham; V Jarlier; R Jones; I Phillips; D Sahm; S Senn; M Struelens; D Taylor; A White
Journal:  Clin Microbiol Infect       Date:  2001-06       Impact factor: 8.067

4.  Worldwide prevalence of antimicrobial resistance in Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis in the SENTRY Antimicrobial Surveillance Program, 1997-1999.

Authors:  D J Hoban; G V Doern; A C Fluit; M Roussel-Delvallez; R N Jones
Journal:  Clin Infect Dis       Date:  2001-05-15       Impact factor: 9.079

5.  Survey of infections due to Staphylococcus species: frequency of occurrence and antimicrobial susceptibility of isolates collected in the United States, Canada, Latin America, Europe, and the Western Pacific region for the SENTRY Antimicrobial Surveillance Program, 1997-1999.

Authors:  D J Diekema; M A Pfaller; F J Schmitz; J Smayevsky; J Bell; R N Jones; M Beach
Journal:  Clin Infect Dis       Date:  2001-05-15       Impact factor: 9.079

6.  Clinical prevalence, antimicrobial susceptibility, and geographic resistance patterns of enterococci: results from the SENTRY Antimicrobial Surveillance Program, 1997-1999.

Authors:  D E Low; N Keller; A Barth; R N Jones
Journal:  Clin Infect Dis       Date:  2001-05-15       Impact factor: 9.079

7.  Resistance surveillance of Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis isolated in Asia and Europe, 1997-1998.

Authors:  D F Sahm; M E Jones; M L Hickey; D R Diakun; S V Mani; C Thornsberry
Journal:  J Antimicrob Chemother       Date:  2000-04       Impact factor: 5.790

Review 8.  Treatment of community-acquired pneumonia.

Authors:  J Bartlett
Journal:  Chemotherapy       Date:  2000       Impact factor: 2.544

9.  Antimicrobial resistance among lower respiratory tract isolates of Haemophilus influenzae: results of a 1992-93 western Europe and USA collaborative surveillance study. The Alexander Project Collaborative Group.

Authors:  G V Doern
Journal:  J Antimicrob Chemother       Date:  1996-07       Impact factor: 5.790

10.  Ampicillin-sulbactam and amoxicillin-clavulanate susceptibility testing of Escherichia coli isolates with different beta-lactam resistance phenotypes.

Authors:  A Oliver; M Pérez-Vázquez; M Martínez-Ferrer; F Baquero; L De Rafael; R Cantón
Journal:  Antimicrob Agents Chemother       Date:  1999-04       Impact factor: 5.191

View more
  2 in total

Review 1.  Amoxicillin/clavulanic acid 2000mg/125mg extended release (XR): a review of its use in the treatment of respiratory tract infections in adults.

Authors:  Paul L McCormack; Gillian M Keating
Journal:  Drugs       Date:  2005       Impact factor: 9.546

2.  New semiphysiological absorption model to assess the pharmacodynamic profile of cefuroxime axetil using nonparametric and parametric population pharmacokinetics.

Authors:  J B Bulitta; C B Landersdorfer; M Kinzig; U Holzgrabe; F Sorgel
Journal:  Antimicrob Agents Chemother       Date:  2009-06-15       Impact factor: 5.191

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.